MSD

News

AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).

News

Merck claims a brace of head and neck cancer approvals

Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day.

News

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app

Views & Analysis

R&D round-up: Non-opioid painkiller space heats up

As the MHRA announced that it would be convening an Expert Working

Sales & Marketing

Breaking new ground in digital content delivery for pharma

It’s all too easy for pharmaceutical processes to slow marketing campaigns, rendering them unmanageable and ineffective, but a ground-breaking initiative is proving that digital content del

Views & Analysis

Inspiring a new generation of women in pharma

As part of a series of articles highlighting the role of women in the pharma industry, Richard Staines speaks to Louise Houson, MSD’s managing director for UK and Ireland

AZ/MSD’s Lynparza sees positive results in prostate cancer

Merck claims a brace of head and neck cancer approvals

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

R&D round-up: Non-opioid painkiller space heats up

Breaking new ground in digital content delivery for pharma

Inspiring a new generation of women in pharma

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

MSD

Editor's Picks